Lercaprel

Enalapril maleate and lercanidipine hydrochloride, the active ingredients in Lercaprel, are an ACE inhibitor and a dihydropyridine calcium‑channel blocker presented as an oral tablet for oral use. The combination is indicated for the management of elevated blood pressure in adult patients. GNH USA supplies Lercaprel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercaprel is an antihypertensive medication that acts on the renin‑angiotensin system and vascular smooth‑muscle calcium channels to lower blood pressure. - Essential hypertension: provides additive reduction of systolic and diastolic pressure. - Isolated systolic hypertension: improves pulse pressure control. - Mixed (systolic/diastolic) hypertension: achieves comprehensive blood‑pressure management.

Lercaprel may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Cough: dry, non‑productive cough. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness of the skin. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure causing faintness. - Liver dysfunction: abnormal liver enzymes or hepatitis. - Acute renal failure: sudden loss of kidney function. - Myocardial infarction: rare occurrence of heart attack. - Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lercaprel, clinicians should assess patient‑specific risk factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of angioedema or severe rash appear. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercaprel can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase risk of renal impairment. - Potassium‑sparing diuretics: may cause hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise lercanidipine plasma levels. - NSAIDs: can blunt antihypertensive effect and affect renal function. - Concurrent ACE inhibitors or ARBs: increase risk of angioedema.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect. - Beta‑blockers: may enhance hypotensive response. - Lithium: risk of lithium toxicity. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce lercanidipine exposure. - Glucocorticoids: may affect fluid balance and blood pressure.